These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26272530)

  • 1. Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma.
    Abdulla S; Saada J; Johnson G; Jefferies S; Ajithkumar T
    Clin Radiol; 2015 Nov; 70(11):1299-312. PubMed ID: 26272530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
    Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
    J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
    Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
    Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
    J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI.
    Chen X; Wei X; Zhang Z; Yang R; Zhu Y; Jiang X
    Clin Imaging; 2015; 39(5):775-80. PubMed ID: 25956436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
    Yildirim M; Baykara M
    Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
    Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
    Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
    Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients.
    Pouleau HB; Sadeghi N; Balériaux D; Mélot C; De Witte O; Lefranc F
    Int J Oncol; 2012 Apr; 40(4):923-8. PubMed ID: 22086066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
    Delgado-López PD; Riñones-Mena E; Corrales-García EM
    Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of the Posttherapeutic Brain.
    Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
    Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
    Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
    Front Immunol; 2021; 12():790674. PubMed ID: 34899760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI perfusion in determining pseudoprogression in patients with glioblastoma.
    Young RJ; Gupta A; Shah AD; Graber JJ; Chan TA; Zhang Z; Shi W; Beal K; Omuro AM
    Clin Imaging; 2013; 37(1):41-9. PubMed ID: 23151413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.